Central Nervous System Lymphoma Treatment Global Market Report 2025

The central nervous system lymphoma treatment market size has grown strongly in recent years. It will grow from $1.19 billion in 2024 to $1.28 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historic period can be attributed to the rising prevalence of central nervous system (CNS) lymphoma, increased adoption of targeted therapies, expansion of cancer awareness programs, higher healthcare expenditure, advancements in immunotherapy, the introduction of high-dose chemotherapy, a surge in clinical trial activities, and improved access to specialized healthcare services.

The central nervous system lymphoma treatment market size is expected to see strong growth in the next few years. It will grow to $1.67 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period is expected to be driven by the increasing demand for personalized medicine, a greater focus on early diagnosis, rising investments in oncology research, the introduction of novel drug delivery systems, expanding healthcare infrastructure in emerging markets, a growing prevalence of autoimmune conditions, the development of combination therapies, increased availability of biosimilars, and the growing adoption of telemedicine for cancer care. Major trends include advancements in precision medicine, the integration of artificial intelligence in diagnosis, the use of liquid biopsy for monitoring, the adoption of nanotechnology-based drug delivery, innovations in imaging technologies, the development of bispecific antibodies, the application of gene editing technologies such as clustered regularly interspaced short palindromic repeats (CRISPR), the implementation of wearable health monitoring devices, and the expansion of telehealth platforms for oncology care.

The rapid expansion of the pharmaceutical industry is expected to drive growth in the central nervous system lymphoma treatment market. This industry focuses on researching, developing, manufacturing, and distributing drugs and medications to prevent, treat, and manage diseases. Its growth is fueled by advancements in medical research, an aging population, increased global healthcare access, rising chronic diseases, global health crises, regulatory support, and higher healthcare spending. The pharmaceutical sector’s expansion fosters innovation in targeted therapies, enhances diagnostic capabilities, and increases investment in research and development for rare cancers, including central nervous system lymphoma. For example, in June 2024, the European Federation of Pharmaceutical Industries and Associations (EFPIA), a Belgium-based trade association representing the pharmaceutical industry, reported that Europe’s total pharmaceutical production reached $417.3 billion (€390,000 million) in 2023, up from $388.14 billion (€363,300 million) in 2022. This rapid growth in the pharmaceutical industry is contributing to advancements in central nervous system lymphoma treatment.

The increasing shift toward personalized medicine is also expected to propel the growth of the central nervous system lymphoma treatment market. Personalized medicine tailors treatments to individual patients based on genetic, environmental, and lifestyle factors, optimizing outcomes and improving care. This demand is driven by advancements in genomics, the availability of biomarker-based diagnostics, improved data analytics technologies, and a rising need for more targeted and effective therapies. In central nervous system lymphoma treatment, personalized medicine allows therapies to be customized to a patient's unique genetic and molecular profile, improving precision, reducing side effects, and increasing the chances of successful treatment, particularly in complex or refractory cases. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the Food and Drug Administration (FDA) approved seven new personalized cancer treatments in 2023, out of a total of 26 personalized treatments, marking a significant rise from the 12 approved in 2022. This growing emphasis on personalized medicine is fueling the expansion of the central nervous system lymphoma treatment market.

Leading companies in the central nervous system lymphoma market are concentrating on innovative therapies, such as chimeric antigen receptor (CAR) T-cell therapy, to enhance treatment effectiveness, provide personalized options, and improve patient outcomes, especially for relapsed or refractory cases. CAR T-cell therapy is an immunotherapy that involves modifying a patient's T-cells to recognize and attack cancer cells more effectively. For example, in June 2024, Kite Pharma, a US-based pharmaceutical company, in collaboration with Dana-Farber Cancer Institute, a US-based cancer treatment center, introduced Yescarta (axicabtagene ciloleucel), a therapy that has shown promising tolerance in patients with relapsed or refractory (R/R) primary or secondary central nervous system lymphoma (PCNSL and SCNSL). Yescarta collects a patient’s T-cells, genetically modifies them to target cancer cells, and reintroduces them into the body to destroy lymphoma cells, including those in the central nervous system. This therapy is particularly effective in treating relapsed or difficult-to-treat cases.

Major players in the central nervous system lymphoma treatment market are Pfizer Inc., Johnson & Johnson, F Hoffmann-La Roche AG, Merck & Co. Inc, AbbVie Inc., Bristol-Myers Squibb, Astrazeneca plc, Novartis AG, GlaxoSmithKline Plc, Gilead Sciences, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Regeneron Pharmaceuticals, Biogen Inc., UCB Pharma, Incyte Corporation, Takeda Pharmaceutical Company Limited, Seagen Inc., MorphoSys AG, Nurix Therapeutics, Fresenius SE & Co KGaA, Astellas Pharma, Sandoz Group AG, BeiGene Ltd.

North America was the largest region in the central nervous system lymphoma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in central nervous system lymphoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the central nervous system lymphoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Central nervous system (CNS) lymphoma treatment involves medical strategies to manage and treat primary or secondary lymphoma affecting the brain, spinal cord, or cerebrospinal fluid (CSF). This treatment typically includes high-dose methotrexate-based chemotherapy, often in combination with other drugs, immunotherapy, radiation therapy, and autologous stem cell transplantation (ASCT). The goal of CNS lymphoma treatment is to eradicate cancer cells while maintaining neurological function and preventing relapse. Treatment plans are customized based on the patient's age, overall health, and disease severity.

The primary treatment methods for CNS lymphoma include chemotherapy, radiation therapy, targeted therapy, corticosteroids, and immunotherapy. Chemotherapy in CNS lymphoma treatment involves using potent anti-cancer drugs to eliminate lymphoma cells within the brain, spinal cord, or other areas of the central nervous system. These drugs can be administered through various routes, including intravenous, oral, and intrathecal delivery. Additionally, distribution channels for these treatments include direct sales and third-party distributors. The key end users of CNS lymphoma treatment include hospitals, clinics, and ambulatory surgical centers.

The central nervous system lymphoma treatment market research report is one of a series of new reports that provides central nervous system lymphoma treatment market statistics, including central nervous system lymphoma treatment industry global market size, regional shares, competitors with a central nervous system lymphoma treatment market share, detailed central nervous system lymphoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system lymphoma treatment industry. This central nervous system lymphoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The central nervous system lymphoma treatment market consists of revenues earned by entities by providing services such as diagnostic testing, stem cell transplants, clinical trials and post-treatment care for patients with central nervous system (CNS) lymphoma. The market value includes the value of related goods sold by the service provider or included within the service offering. The central nervous system lymphoma treatment market also includes sales of radiation equipment, diagnostic tools, and supportive care medications used in the treatment of central nervous system (CNS) lymphoma. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.